Enovis (NYSE:ENOV – Get Free Report) was downgraded by research analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research note issued to investors on Tuesday,Zacks.com reports.
Several other equities analysts have also commented on the stock. Evercore reissued an “outperform” rating and issued a $36.00 target price on shares of Enovis in a report on Friday, May 8th. William Blair started coverage on shares of Enovis in a research note on Friday, April 17th. They issued an “outperform” rating on the stock. BTIG Research restated a “buy” rating and set a $39.00 price objective on shares of Enovis in a research report on Friday, May 22nd. Weiss Ratings restated a “sell (e+)” rating on shares of Enovis in a research note on Friday, April 10th. Finally, Wells Fargo & Company reduced their target price on Enovis from $42.00 to $40.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. Seven investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $44.50.
View Our Latest Stock Analysis on ENOV
Enovis Stock Performance
Enovis (NYSE:ENOV – Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.89 EPS for the quarter, topping analysts’ consensus estimates of $0.82 by $0.07. The company had revenue of $589.15 million for the quarter, compared to analysts’ expectations of $572.02 million. Enovis had a positive return on equity of 10.32% and a negative net margin of 49.92%.Enovis’s revenue was up 5.4% on a year-over-year basis. During the same quarter last year, the business earned $0.81 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Sell-side analysts expect that Enovis will post 3.12 EPS for the current fiscal year.
Insider Transactions at Enovis
In related news, insider Oliver Engert acquired 1,200 shares of the stock in a transaction that occurred on Thursday, June 11th. The stock was acquired at an average cost of $21.62 per share, for a total transaction of $25,944.00. Following the transaction, the insider directly owned 51,840 shares in the company, valued at $1,120,780.80. This trade represents a 2.37% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last ninety days, insiders have purchased 4,200 shares of company stock worth $92,084. 2.90% of the stock is owned by corporate insiders.
Institutional Trading of Enovis
Hedge funds have recently added to or reduced their stakes in the stock. Rubric Capital Management LP bought a new stake in shares of Enovis during the third quarter worth $83,435,000. Paradigm Capital Management Inc. NY lifted its stake in shares of Enovis by 70.2% in the 1st quarter. Paradigm Capital Management Inc. NY now owns 1,776,715 shares of the company’s stock valued at $40,420,000 after acquiring an additional 732,917 shares during the last quarter. AQR Capital Management LLC boosted its holdings in shares of Enovis by 682.6% during the 2nd quarter. AQR Capital Management LLC now owns 498,317 shares of the company’s stock valued at $15,627,000 after acquiring an additional 434,646 shares in the last quarter. Front Street Capital Management Inc. boosted its holdings in shares of Enovis by 106.1% during the 1st quarter. Front Street Capital Management Inc. now owns 746,056 shares of the company’s stock valued at $16,973,000 after acquiring an additional 384,124 shares in the last quarter. Finally, Quantinno Capital Management LP grew its position in Enovis by 130.8% during the 1st quarter. Quantinno Capital Management LP now owns 604,500 shares of the company’s stock worth $13,752,000 after acquiring an additional 342,556 shares during the last quarter. Institutional investors and hedge funds own 98.45% of the company’s stock.
Enovis Company Profile
Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.
The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.
Featured Articles
- Five stocks we like better than Enovis
- AirJoule Unveils Prime System, Clearing Path to Commercialization
- Copper Stocks Are Getting a Bigger Spotlight as Gold’s Rally Cracks
- Nike Q4 Beat Masks Core Weakness as Analysts Cut Price Targets
- Uber’s Waymo Detour Tests the Stock’s Robotaxi Bull Case
Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.
